
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Common Stock
OSE Immunotherapeutics SA
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Common Stock
€4.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
![]() |
Valneva SE
PAR:VLA
|
Common Stock
€24.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Common Stock
€1.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
G
|
Genfit SA
PAR:GNFT
|
Common Stock
€12.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Common Stock
€525k
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Common Stock
€3.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Common Stock?
Common Stock
4.4m
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Common Stock amounts to 4.4m EUR.
What is OSE Immunotherapeutics SA's Common Stock growth rate?
Common Stock CAGR 10Y
11%
Over the last year, the Common Stock growth was 1%. The average annual Common Stock growth rates for OSE Immunotherapeutics SA have been 6% over the past three years , 8% over the past five years , and 11% over the past ten years .